stoxline Quote Chart Rank Option Currency Glossary
  
Salarius Pharmaceuticals, Inc. (SLRX)
1.71  -0.1 (-5.52%)    02-12 19:26
Open: 1.81
High: 1.8102
Volume: 61,350
  
Pre. Close: 1.81
Low: 1.71
Market Cap: 3(M)
Technical analysis
2025-02-12 4:48:05 PM
Short term     
Mid term     
Targets 6-month :  5.88 1-year :  8.4
Resists First :  5.04 Second :  7.19
Pivot price 2.17
Supports First :  1.54 Second :  1.28
MAs MA(5) :  1.84 MA(20) :  2.28
MA(100) :  1.72 MA(250) :  2.67
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  1.4 D(3) :  1.4
RSI RSI(14): 40.1
52-week High :  7.19 Low :  1.22
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ SLRX ] has closed above bottom band by 9.2%. Bollinger Bands are 53.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.81 - 1.82 1.82 - 1.84
Low: 1.68 - 1.69 1.69 - 1.71
Close: 1.69 - 1.71 1.71 - 1.73
Company Description

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Headline News

Mon, 03 Feb 2025
Salarius Pharmaceuticals Announces Patient Enrollment to - GlobeNewswire

Mon, 03 Feb 2025
Breakthrough Cancer Treatment Shows Triple Survival Time: Trial Back on Track - StockTitan

Mon, 13 Jan 2025
Gold Down Over 1%; Salarius Pharmaceuticals Shares Surge - Benzinga

Mon, 13 Jan 2025
Salarius Pharmaceuticals Merges with Decoy Therapeutics - TipRanks

Mon, 13 Jan 2025
Shareholder Alert: Ademi LLP investigates whether Salarius Pharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire

Mon, 13 Jan 2025
Salarius Pharma Merges with AI Drug Designer Decoy Therapeutics, Plans Pan-Coronavirus Drug - StockTitan

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 2 (M)
Shares Float 1 (M)
Held by Insiders 2.5 (%)
Held by Institutions 0.3 (%)
Shares Short 65 (K)
Shares Short P.Month 15 (K)
Stock Financials
EPS -5.14
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 10.73
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -54 %
Return on Equity (ttm) -119.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -4.26
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -0.34
PEG Ratio 0
Price to Book value 0.15
Price to Sales 0
Price to Cash Flow -0.36
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android